Tesamorelin and Visceral Fat: The Trial Record

Recherche sur les hormones, l'hormone de croissance et la composition corporelle

Tesamorelin is an approved medication, which means its evidence is measured in large randomized trials rather than early reports. Two of them, published in AIDS, quantify its effect on visceral fat.

View product →

Findings

• Tesamorelin is an approved medication, tested in large randomized placebo-controlled trials.
• In those trials it reduced visceral fat (the deep belly fat around the organs) by about 18%, versus essentially no change on placebo.
• Blood triglycerides also fell substantially.
• The effect holds while treatment continues and reverses after stopping.

The 52-week trial (AIDS, 2008)

HIV patients with central fat accumulation were randomized to tesamorelin 2 mg or placebo daily. Over 52 weeks, visceral adipose tissue fell 18% and triglycerides fell 51 mg/dl versus baseline (both P<0.001). Total cholesterol also improved, and the treatment was generally well tolerated with glucose parameters not clinically affected. The visceral-fat reduction was sustained during treatment, though it reaccumulated once tesamorelin was stopped.

The modern-regimen trial (AIDS, 2024)

Because the original Phase 3 work predated integrase-inhibitor therapy, a newer randomized, double-blind study re-examined tesamorelin in people on those regimens. Over 12 months it produced significant declines in visceral fat (median -25 cm² vs +14 on placebo, P=0.001), hepatic fat (-4.2% vs -0.5%, P=0.01), and trunk-to-appendicular fat ratio, with no worsening of glycemic control.

What tesamorelin is

Tesamorelin is a stabilized analogue of growth hormone-releasing hormone (GHRH). It prompts the body’s own pulsatile growth-hormone release rather than supplying growth hormone directly, which is the mechanism behind its effect on visceral fat. Our tesamorelin explainer covers the GHRH mechanism, and our comparison with CJC-1295 and ipamorelin places it among the growth-hormone-axis peptides.

Frequently asked questions

What did tesamorelin do to visceral fat in trials?

In a 52-week randomized trial of people with HIV and abdominal fat accumulation, tesamorelin produced a sustained 18% reduction in visceral adipose tissue and a 51 mg/dl fall in triglycerides versus baseline. A 2024 trial confirmed significant visceral and liver-fat reductions on modern HIV regimens.

Is tesamorelin an approved medication?

Yes. Tesamorelin is FDA-approved to treat abdominal fat accumulation in people with HIV, which is why its trial record is unusually complete for a research peptide.

Does the effect last after stopping?

In the 52-week study, the reduction in visceral fat was sustained throughout treatment, but visceral fat reaccumulated after tesamorelin was discontinued.

Sources: Falutz J, et al. Long-term safety and effects of tesamorelin in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719-1728. PMID 18690162. Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38:1758-1765. PMID 38905488.